Literature DB >> 22922998

What is measured with verbal fluency tests in Parkinson's disease patients at different stages of the disease?

Janneke Koerts1, Hester A Meijer, Katrien S F Colman, Lara Tucha, Klaus W Lange, Oliver Tucha.   

Abstract

Verbal fluency tests (VFT) are often used to assess executive functioning in Parkinson's disease (PD). Various cognitive functions may, however, impair performance on VFT. Furthermore, since PD is a progressive neurodegenerative disease, it is also not clear whether deficits on VFT reflect impairments in the same cognitive functions throughout the different disease stages. This study will investigate what is measured with VFT in PD, in particular at different disease stages. Eighty-eight PD patients and 65 healthy participants, matched for age, gender, and education, were included. All were assessed with semantic and phonemic VFT and tests assessing executive functions, memory, and psychomotor speed. Mild and moderate PD patients did not differ in the number of words generated on both VFT. However, mild and moderate PD patients differed significantly with regard to the size of the largest cluster and the number of intra-dimensional shifts on phonemic VFT. Furthermore, at the mild disease stages, psychomotor speed predicted the performance on both VFT; whereas at the moderate stages of the disease, cognitive flexibility and psychomotor speed predicted the performance on both VFT. In conclusion, different cognitive functions underlie the performances of PD patients at different stages of the disease on semantic and phonemic VFT. Impairments in VFT, therefore, do not necessarily represent a specific deficit of executive functioning in patients with PD but should rather be interpreted in the context of disease severity and dysfunctions in other domains of cognition.

Entities:  

Mesh:

Year:  2012        PMID: 22922998     DOI: 10.1007/s00702-012-0885-9

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  25 in total

1.  Normative data for clustering and switching on verbal fluency tasks.

Authors:  A K Troyer
Journal:  J Clin Exp Neuropsychol       Date:  2000-06       Impact factor: 2.475

2.  [Letter fluency: psychometric properties and Dutch normative data].

Authors:  B Schmand; S C Groenink; M van den Dungen
Journal:  Tijdschr Gerontol Geriatr       Date:  2008-04

3.  Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways.

Authors:  R Hilker; A V Thomas; J C Klein; S Weisenbach; E Kalbe; L Burghaus; A H Jacobs; K Herholz; W D Heiss
Journal:  Neurology       Date:  2005-12-13       Impact factor: 9.910

4.  The effect of Parkinson's disease on the ability to maintain a mental set.

Authors:  K A Flowers; C Robertson
Journal:  J Neurol Neurosurg Psychiatry       Date:  1985-06       Impact factor: 10.154

5.  Cognitive profile of patients with newly diagnosed Parkinson disease.

Authors:  Dino Muslimovic; Bart Post; Johannes D Speelman; Ben Schmand
Journal:  Neurology       Date:  2005-10-25       Impact factor: 9.910

6.  The validity of the Hamilton and Montgomery-Asberg depression rating scales as screening and diagnostic tools for depression in Parkinson's disease.

Authors:  A F Leentjens; F R Verhey; R Lousberg; H Spitsbergen; F W Wilmink
Journal:  Int J Geriatr Psychiatry       Date:  2000-07       Impact factor: 3.485

7.  Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis.

Authors:  D Aarsland; K Bronnick; C Williams-Gray; D Weintraub; K Marder; J Kulisevsky; D Burn; P Barone; J Pagonabarraga; L Allcock; G Santangelo; T Foltynie; C Janvin; J P Larsen; R A Barker; M Emre
Journal:  Neurology       Date:  2010-09-21       Impact factor: 9.910

8.  Course of cognitive decline in Parkinson's disease: a meta-analysis.

Authors:  Dino Muslimović; Ben Schmand; Johannes D Speelman; Rob J de Haan
Journal:  J Int Neuropsychol Soc       Date:  2007-11       Impact factor: 2.892

9.  Executive functioning in daily life in Parkinson's disease: initiative, planning and multi-task performance.

Authors:  Janneke Koerts; Marije Van Beilen; Oliver Tucha; Klaus L Leenders; Wiebo H Brouwer
Journal:  PLoS One       Date:  2011-12-20       Impact factor: 3.240

Review 10.  Evolution of cognitive dysfunction in an incident Parkinson's disease cohort.

Authors:  C H Williams-Gray; T Foltynie; C E G Brayne; T W Robbins; R A Barker
Journal:  Brain       Date:  2007-05-29       Impact factor: 13.501

View more
  5 in total

Review 1.  Fragile X-associated tremor/ataxia syndrome: phenotypic comparisons with other movement disorders.

Authors:  Erin E Robertson; Deborah A Hall; Andrew R McAsey; Joan A O'Keefe
Journal:  Clin Neuropsychol       Date:  2016-08       Impact factor: 3.535

2.  The effect of Parkinson's disease subgroups on verbal and nonverbal fluency.

Authors:  Abhishek Jaywant; Giovanni Musto; Sandy Neargarder; Karina Stavitsky Gilbert; Alice Cronin-Golomb
Journal:  J Clin Exp Neuropsychol       Date:  2014-02-17       Impact factor: 2.475

3.  Virtual multiple errands test (VMET): a virtual reality-based tool to detect early executive functions deficit in Parkinson's disease.

Authors:  Pietro Cipresso; Giovanni Albani; Silvia Serino; Elisa Pedroli; Federica Pallavicini; Alessandro Mauro; Giuseppe Riva
Journal:  Front Behav Neurosci       Date:  2014-12-05       Impact factor: 3.558

4.  Semantic fluency and processing speed are reduced in non-cognitively impaired participants with Parkinson's disease.

Authors:  Brenna A Cholerton; Kathleen L Poston; Laurice Yang; Liana S Rosenthal; Ted M Dawson; Alexander Pantelyat; Karen L Edwards; Lu Tian; Joseph F Quinn; Kathryn A Chung; Amie L Hiller; Shu-Ching Hu; Thomas J Montine; Cyrus P Zabetian
Journal:  J Clin Exp Neuropsychol       Date:  2021-08-06       Impact factor: 2.283

5.  Striatal volume is related to phonemic verbal fluency but not to semantic or alternating verbal fluency in early Parkinson's disease.

Authors:  Ulla Ellfolk; Juho Joutsa; Juha O Rinne; Riitta Parkkola; Pekka Jokinen; Mira Karrasch
Journal:  J Neural Transm (Vienna)       Date:  2013-08-03       Impact factor: 3.575

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.